- Home
- ARAY vs GOSS Comparison
ARAY vs GOSS Comparison
Compare ARAY & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARAY
- GOSS
- Stock Information
- Founded
- ARAY 1990
- GOSS 2015
- Country
- ARAY United States
- GOSS United States
- Employees
- ARAY N/A
- GOSS N/A
- Industry
- ARAY Medical/Dental Instruments
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- ARAY Health Care
- GOSS Health Care
- Exchange
- ARAY Nasdaq
- GOSS Nasdaq
- Market Cap
- ARAY 229.3M
- GOSS 203.3M
- IPO Year
- ARAY 2007
- GOSS 2019
- Fundamental
- Price
- ARAY $1.59
- GOSS $1.26
- Analyst Decision
- ARAY
- GOSS Strong Buy
- Analyst Count
- ARAY 0
- GOSS 4
- Target Price
- ARAY N/A
- GOSS $7.75
- AVG Volume (30 Days)
- ARAY 673.3K
- GOSS 1.4M
- Earning Date
- ARAY 04-30-2025
- GOSS 05-15-2025
- Dividend Yield
- ARAY N/A
- GOSS N/A
- EPS Growth
- ARAY N/A
- GOSS N/A
- EPS
- ARAY 0.01
- GOSS N/A
- Revenue
- ARAY $465,251,000.00
- GOSS $124,590,000.00
- Revenue This Year
- ARAY $3.87
- GOSS N/A
- Revenue Next Year
- ARAY $0.09
- GOSS $190.37
- P/E Ratio
- ARAY $237.85
- GOSS N/A
- Revenue Growth
- ARAY 8.06
- GOSS N/A
- 52 Week Low
- ARAY $1.28
- GOSS $0.50
- 52 Week High
- ARAY $2.95
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- ARAY 51.00
- GOSS 62.39
- Support Level
- ARAY $1.49
- GOSS $1.09
- Resistance Level
- ARAY $1.77
- GOSS $1.20
- Average True Range (ATR)
- ARAY 0.07
- GOSS 0.09
- MACD
- ARAY 0.00
- GOSS 0.01
- Stochastic Oscillator
- ARAY 35.71
- GOSS 90.07
About ARAY Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.